Stockreport

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap [Seeking Alpha]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway exten [Read more]